Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | PDCD1 | Q15116 | 10/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 10/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1496999 | 0.95 | KMT2A (0.44) | ACHEBACE1PDCD1CD274ACKR3 | |
| SCHEMBL1496840 | 0.94 | ACKR3 (0.44) | ACHEBACE1PDCD1CD274ACKR3 | |
| SCHEMBL1482729 | 0.92 | ALDH1A1 (0.44) | PDCD1CD274ACKR3KMT2A | |
| SCHEMBL3229584 | 0.92 | PDCD1 (0.47) | ACHEBACE1PDCD1CD274ACKR3 | |
| SCHEMBL1497450 | 0.90 | CD274 (0.43) | PDCD1CD274ACKR3KMT2ADRD2 | |
| SCHEMBL3224383 | 0.90 | PDCD1 (0.46) | ACHEBACE1PDCD1CD274HDAC1 | |
| SCHEMBL1496876 | 0.89 | CSF1R (0.42) | PDCD1CD274ACKR3HDAC1NAMPT | |
| SCHEMBL1497451 | 0.87 | CD274 (0.47) | PDCD1CD274HDAC1NAMPTKMT2A | |
| SCHEMBL3218971 | 0.86 | PDCD1 (0.46) | PDCD1CD274ACKR3HDAC1KMT2A | |
| SCHEMBL12249896 | 0.84 | HTT (0.46) | PDCD1CD274HDAC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288380-B2 | Thiophenediamine derivative having urea structure | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120202808-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| US-20120202808-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| EP-2292611-B1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-8198271-B2 | Thiophenediamine derivative having urea structure | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20110077244-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-31 | — | — | US | disclosed |
| EP-2292611-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | Santen Pharmaceutical Co., Ltd (JP) | 2011-03-09 | — | — | EP | disclosed |
| WO-2009142321-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | 参天製薬株式会社 (JP) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202808-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | CBR1, NAT1, PRMT1 | ACHE 1166/4885BACE1 3817/4885PDCD1 4160/4885 |
| US-20110077244-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | HNMT, HRH4, CHRM1 | ACHE 979/4885BACE1 3171/4885PDCD1 4547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.